Aperture Venture Partners IV, L.P. 4
4 · Trevi Therapeutics, Inc. · Filed May 13, 2019
Insider Transaction Report
Form 4
Aperture Venture Partners IV, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2019-05-09+232,963→ 232,963 total - Conversion
Series C Preferred Stock
2019-05-09−2,054,795→ 0 total→ Common Stock (232,963 underlying) - Purchase
Common Stock
2019-05-09$10.00/sh+112,000$1,120,000→ 344,963 total
Footnotes (2)
- [F1]On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P.